| 10.10 08:13 | dpa-AFX: *DEUTSCHE BANK RESEARCH RAISES SANOFI PRICE TARGET TO 90 (85) EUR - 'SELL' |
| 10.10 08:13 | dpa-AFX: *DEUTSCHE BANK RESEARCH HEBT ZIEL FÜR SANOFI AUF 90 (85) EUR - 'SELL' |
| 10.10 05:15 | dpa-AFX: WDH/GSK einigt sich bei Tausenden US-Zantac-Klagen - Milliardenzahlung |
| 09.10 19:22 | dpa-AFX: GSK einigt sich bei Tausenden US-Zantac-Klagen - Milliardenzahlung |
| 09.10 19:22 | GSK einigt sich bei Tausenden US-Zantac-Klagen - Milliardenzahlung |
| 09.10 19:17 | dpa-AFX: GSK einigt sich bei Tausenden US-Zantac-Klagen - Milliardenzahlung |
| 09.10 07:35 | dpa-AFX: Sanofi : Beyfortus Data Reinforce Effectiveness Against RSV Disease & Hospitalization In Infants |
| 09.10 07:23 | dpa-AFX: *SANOFI : BEYFORTUS DATA REINFORCE EFFECTIVENESS AGAINST RSV DISEASE AND HOSPITALIZATION IN INFANTS |
| 09.10 07:00 | dpa-AFX: GNW-Adhoc: Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants |
| 04.10 08:59 | Recordati kauft Sanofi Enjaymo-Rechte für 825 Millionen Dollar ab |
| 04.10 07:58 | dpa-AFX: *RECORDATI ACQUIRES GLOBAL RIGHTS TO ENJAYMO FROM SANOFI |
| 03.10 06:59 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt Sanofi auf 'Neutral' - Ziel 100 Euro |
| 03.10 06:59 | dpa-AFX: JPMorgan belässt Sanofi auf 'Neutral' - Ziel 100 Euro |
| 27.09 16:51 | dpa-AFX: Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment |
| 27.09 16:11 | Sanofi und Regeneron erhalten US-Zulassung für Dupixent bei COPD |
| 27.09 15:52 | dpa-AFX: *REGENERON & SANOFI : DUPIXENT APPROVED IN U.S. FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT |
| 27.09 15:35 | dpa-AFX: GNW-Adhoc: Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD |
| 27.09 13:36 | dpa-AFX: Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease |
| 27.09 13:05 | dpa-AFX: *REGENERON PHARMA AND SANOFI: NMPA IN CHINA APPROVES DUPIXENT FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| 27.09 13:00 | dpa-AFX: GNW-Adhoc: Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD |
|
|
